10.1007/s40204-017-0064-z

Nanotechnology for the treatment of melanoma skin cancer

HTML PDF
  • Lucas B. Naves1,
  • Chetna Dhand2,
  • Jayarama Reddy Venugopal3,
  • Lakshminarayanan Rajamani2,
  • Seeram Ramakrishna4,
  • Luis Almeida*5,
  1. CAPES Foundation, Ministry of Education of Brazil, Brasília, BR Centre for Textile Science and Technology, University of Minho, Braga, PT Department of Mechanical Engineering, Center for Nanofibers & Nanotechnology, National University of Singapore, Singapore, 117576, SG
  2. Anti-Infectives Research Group, Singapore Eye Research Institute, Singapore, 169856, SG
  3. Department of Mechanical Engineering, Center for Nanofibers & Nanotechnology, National University of Singapore, Singapore, 117576, SG
  4. Department of Mechanical Engineering, Center for Nanofibers & Nanotechnology, National University of Singapore, Singapore, 117576, SG Guangdong-Hongkong-Macau Institute of CNS Regeneration (GHMICR), Jinan University, Guangzhou, 510632, CN
  5. Centre for Textile Science and Technology, University of Minho, Braga, PT
Cover Image

Published in Issue 2017-03-16

How to Cite

Naves, L. B., Dhand, C., Venugopal, J. R., Rajamani, L., Ramakrishna, S., & Almeida, L. (2017). Nanotechnology for the treatment of melanoma skin cancer. Progress in Biomaterials, 6(1-2 (May 2017). https://doi.org/10.1007/s40204-017-0064-z
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Abstract Melanoma is the most aggressive type of skin cancer and has very high rates of mortality. An early stage melanoma can be surgically removed, with a survival rate of 99%. This literature review intends to elucidate the possibilities to treat melanoma skin cancer using hybrid nanofibers developed by advanced electrospinning process. In this review we have shown that the enhanced permeability and retention is the basis for using nanotechnology, aiming topical drug delivery. The importance of the detection of skin cancer in the early stages is directly related to non-metastatic effects and survival rates of melanoma cells. Inhibitors of protein kinase are already available in the market for melanoma treatment and are approved by the FDA; these agents are cobimetinib, dabrafenib, ipilimumab, nivolumab, trametinib, and vemurafenib. We also report a case study involving two different approaches for targeting melanoma skin cancer therapy, namely, magnetic-based core–shell particles and electrospun mats.

Keywords

  • Chemotherapy,
  • Drug delivery systems,
  • Kinase inhibitors,
  • Skin cancer therapy,
  • Topical delivery
HTML PDF

References

  1. Aboofazeli and Lawrence (1994) Investigations into the formation and characterization of phospholipid microemulsions. II. Pseudo-ternary phase diagrams of systems containing water-lecithin-isopropyl myristate and alcohol: influence of purity of lecithin (pp. 51-61) https://doi.org/10.1016/0378-5173(94)90275-5
  2. Aboofazeli et al. (1995) Investigations into the formation and characterization of phospholipid microemulsions. IV. Pseudo-ternary phase diagrams of systems containing water-lecithin-alcohol and oil; the influence of oil (pp. 10-116) https://doi.org/10.1016/0378-5173(95)00125-3
  3. Attwood et al. (1992) Phase studies on oil-in-water phospholipid microemulsions https://doi.org/10.1016/0378-5173(92)90063-8
  4. Balaji and Chempakam (2010) Toxicity prediction of compounds from turmeric (Curcuma longa L) (pp. 2951-2959) https://doi.org/10.1016/j.fct.2010.07.032
  5. Barnes et al. (2007) Nanofiber technology: designing the next generation of tissue engineering scaffolds 59(14) (pp. 1413-1433) https://doi.org/10.1016/j.addr.2007.04.022
  6. Bognitzki et al. (2001) Nanostructured fibers via electrospinning (pp. 70-72) https://doi.org/10.1002/1521-4095(200101)13:1<70::AID-ADMA70>3.0.CO;2-H
  7. Brys et al. (2016) Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy (pp. 565-577) https://doi.org/10.1016/j.biotechadv.2016.01.004
  8. Caldorera-Moore et al. (2010) Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers 7(4) (pp. 479-495) https://doi.org/10.1517/17425240903579971
  9. D’Orazio et al. (2013) UV radiation and the skin (pp. 12222-12248) https://doi.org/10.3390/ijms140612222
  10. Danhier et al. (2009) Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles (pp. 166-173) https://doi.org/10.1016/j.jconrel.2009.08.011
  11. Danielsson and Lindman (1981) The definition of microemulsion (pp. 391-392) https://doi.org/10.1016/0166-6622(81)80064-9
  12. Eggermont et al. (2014) Cutaneous melanoma 383(9919) (pp. 816-827) https://doi.org/10.1016/S0140-6736(13)60802-8
  13. Elias and Menon (1991) Structural and lipid biochemical correlates of the epidermal permeability barrier (pp. 1-26) https://doi.org/10.1016/B978-0-12-024924-4.50005-5
  14. Erdogan (2009) Liposomal nanocarriers for tumor imaging 5(2) (pp. 141-150) https://doi.org/10.1166/jbn.2009.1016
  15. Garbe C, Eigentler TK (2007). Diagnosis and treatment of cutaneous melanoma: state of the art 2006*. Melano Res. 17: 117–127.
  16. http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00008390-200704000-00007npapers3://publication/doi/10.1097/CMR.0b013e328042bb36
  17. Green (1991) Premature ageing of the skin in a Queensland population 155(7) (pp. 473-475)
  18. Guo et al. (2011) Preparation of curcumin loaded poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) nanofibers and their in vitro antitumor activity against Glioma 9L cells (pp. 3825-3832) https://doi.org/10.1039/c1nr10484e
  19. Haley and Frenkel (2008) Nanoparticles for drug delivery in cancer treatment (pp. 57-64) https://doi.org/10.1016/j.urolonc.2007.03.015
  20. Hanson et al. (2002) Two-photon fluorescence lifetime imaging of the skin stratum corneum pH gradient (pp. 1682-1690) https://doi.org/10.1016/S0006-3495(02)73936-2
  21. Harbert CJ, Morrison RF (1944). United States Patent Office 2,600,175
  22. Health, N. C. I. at the N. I. of. (n.d.-a). Cobimetinib.
  23. http://www.cancer.gov/about-cancer/treatment/drugs/cobimetinib
  24. . Accessed 13 Mar 2016
  25. Health, N. C. I. at the N. I. of. (n.d.-b). Dabrafenib.
  26. http://www.cancer.gov/about-cancer/treatment/drugs/dabrafenib
  27. . Accessed 13 Mar 2016
  28. Health, N. C. I. at the N. I. of. (n.d.-c). Ipilimumab.
  29. http://www.cancer.gov/about-cancer/treatment/drugs/ipilimumab
  30. . Accessed 13 Mar 2016
  31. Health, N. C. I. at the N. I. of. (n.d.-d). Nivolumab.
  32. http://www.cancer.gov/about-cancer/treatment/drugs/nivolumab
  33. . Accessed 13 Mar 2016
  34. Health, N. C. I. at the N. I. of. (n.d.-e). Trametinib.
  35. http://www.cancer.gov/about-cancer/treatment/drugs/trametinib
  36. . Accessed 13 Mar 2016
  37. Health, N. C. I. at the N. I. of. (n.d.-f). Vermurafenib.
  38. http://www.cancer.gov/about-cancer/treatment/drugs/vemurafenib
  39. . Accessed 13 Mar 2016
  40. Jain (2013) Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers 31(17) (pp. 2205-2218) https://doi.org/10.1200/JCO.2012.46.3653
  41. Jones and Harris (1998) New developments in angiogenesis: a major mechanism for tumor growth and target for therapy 4(4) (pp. 209-217)
  42. Kreilgaard (2002) Influence of microemulsions on cutaneous drug delivery 54(Suppl 1) (pp. 77-98) https://doi.org/10.1016/S0169-409X(02)00116-3
  43. Krishna and Mayer (2000) Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs 11(4) (pp. 265-283) https://doi.org/10.1016/S0928-0987(00)00114-7
  44. Li et al. (2010) Cell culture processes for monoclonal antibody production 2(5) (pp. 466-479) https://doi.org/10.4161/mabs.2.5.12720
  45. Liu et al. (2007) Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles 120(12) (pp. 2527-2537) https://doi.org/10.1002/ijc.22709
  46. Ma et al. (2007) Magnetic targeting after femoral artery administration and biocompatibility assessment of super paramagnetic iron oxide nanoparticles 84(3) (pp. 598-606) https://doi.org/10.1002/jbm.a.31346
  47. Maeda (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting (pp. 189-207) https://doi.org/10.1016/S0065-2571(00)00013-3
  48. Maeda (2012) Macromolecular therapeutics in cancer treatment: the EPR effect and beyond 164(2) (pp. 138-144) https://doi.org/10.1016/j.jconrel.2012.04.038
  49. Maeda et al. (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review 65(1–2) (pp. 271-284) https://doi.org/10.1016/S0168-3659(99)00248-5
  50. Moghimi et al. (2001) Long-circulating and target-specific nanoparticles: theory to practice 53(2) (pp. 283-318)
  51. Murphy et al. (2010) Dynamic light scattering investigations of nanoparticle aggregation following a light-induced pH jump https://doi.org/10.1063/1.3425883
  52. Unknown (2007) National Institutes of Health
  53. Naves and Almeida (2015) LAP LAMBERT Academic Publishing
  54. Ojea-Jimenez et al. (2013) Engineered inorganic nanoparticles for drug delivery applications (pp. 518-530) https://doi.org/10.2174/13892002113149990008
  55. Pike RD (1999). Superfine microfiber nonwoven web. US Patent 5935883 A
  56. Prow et al. (2011) Nanoparticles and microparticles for skin drug delivery 63(6) (pp. 470-491) https://doi.org/10.1016/j.addr.2011.01.012
  57. Ramakrishna et al. (2006) Electrospun nanofibers: solving global issues 9(3) (pp. 40-50) https://doi.org/10.1016/S1369-7021(06)71389-X
  58. Rauscher H, Roebben G. (2010). Considerations on a definition of nanomaterial for regulatory purposes. JRC Reference Reports. Vol. 24403.
  59. http://lerenard.info/dgs/jrc/downloads/jrc_reference_report_201007_nanomaterials.pdf
  60. Ravichandran et al. (2012) Advances in polymeric systems for tissue engineering and biomedical applications 12(3) (pp. 286-311) https://doi.org/10.1002/mabi.201100325
  61. Reddy et al. (2000) Does epidermal turnover reduce percutaneous penetration? 17(11) (pp. 1414-1419) https://doi.org/10.1023/A:1007522200422
  62. Roy et al. (1996) Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design (pp. 491-495) https://doi.org/10.1021/js950415w
  63. Schmid-Wendtner and Korting (2006) The pH of the skin surface and its impact on the barrier function 19(6) (pp. 296-302) https://doi.org/10.1159/000094670
  64. SEC (2008). Regulatory Aspects of Nanomaterials. Comm Eur Commun 1–11.
  65. http://onlinelibrary.wiley.com/doi/10.1002/cbdv.200490137/abstract
  66. Tinkle et al. (2003) Skin as a route of exposure and sensitization in chronic beryllium disease 111(9) (pp. 1202-1208) https://doi.org/10.1289/ehp.5999
  67. Tran et al. (2009) Use of liposomes as drug delivery vehicles for treatment of melanoma (pp. 388-399) https://doi.org/10.1111/j.1755-148X.2009.00581.x
  68. Trotta et al. (1994) Transcutaneous diffusion of haematoporphyrin in photodynamic therapy in vitro release from microemulsions (pp. 150-154)
  69. Vasir and Labhasetwar (2005) Targeted drug delivery in cancer therapy (pp. 363-374) https://doi.org/10.1177/153303460500400405
  70. Wadajkar et al. (2012) Multifunctional particles for melanoma-targeted drug delivery (pp. 2996-3004) https://doi.org/10.1016/j.actbio.2012.04.042
  71. Wang et al. (2015) Enhanced bioavailability and anticancer effect of curcumin-loaded electrospun nanofiber: in vitro and In vivo study https://doi.org/10.1186/s11671-015-1146-2
  72. Zamani et al. (2013) Advances in drug delivery via electrospun and electrosprayed nanomaterials (pp. 2997-3017) https://doi.org/10.2147/IJN.S43575
  73. Zeng et al. (2003) Biodegradable electrospun fibers for drug delivery (pp. 227-231) https://doi.org/10.1016/S0168-3659(03)00372-9
  74. Zhang et al. (2005) Recent development of polymer nanofibers for biomedical and biotechnological applications (pp. 933-946) https://doi.org/10.1007/s10856-005-4428-x
  75. Zong et al. (2002) Structure and process relationship of electrospun bioabsorbable nanofiber membranes (pp. 4403-4412) https://doi.org/10.1016/S0032-3861(02)00275-6